Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00359866
Status:
COMPLETED
Last Update Posted:
2016-06-15
First Post:
2006-08-02
Brief Title:
Pelvic IMRT With Tomotherapy A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Study Overview
Official Title:
Pelvic IMRT With Tomotherapy A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients
Status:
COMPLETED
Status Verified Date:
2016-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Indications for post-hysterectomy radiation therapy RT have been well established by clinical data Adjuvant RT has demonstrated local control and survival benefit In patients with nodal disease adjuvant chemotherapy concurrent with radiation has further improved the clinical outcome The acute hematological and gastrointestinal toxicity of concurrent chemo-radiotherapy can be quite high sometimes preventing patients from completed their full treatment course potentially compromising the therapeutic benefit of treatment Intensity modulated radiation therapy IMRT is an advanced method of delivering external beam radiation that may minimize the volume of normal tissue irradiated to high dose and thus decrease the risk of normal tissue toxicity Helical tomotherapy is a novel treatment device with sophisticated imaging and treatment delivery features that are optimally suited for IMRT There are retrospective clinical data supporting the use of non-tomotherapy delivered IMRT to treat patients with gynecologic cancers The proposed study will prospectively test whether helical tomotherapy is a feasible method for delivering IMRT in post-hysterectomy cervical cancer patients receiving adjuvant RT Here the question of feasibility is simply one of verifying that target volumes are reliably covered by sculpted IMRT high-dose regions Although this is not a treatment effectiveness study we will also follow the clinical outcome of these patients including toxicity local control and survival in anticipation that this information will be valuable if the treatment modality is judged feasible and will be used for further treatments of this patient population
Detailed Description:
Patients with cervical cancer receiving post-operative radiotherapy RT for high risk features found on pathologic review will be treated with pelvic intensity modulated radiation therapy IMRT Helical tomotherapy will be used to plan and deliver the radiation treatment Treatment volume will include the upper third of the vagina and para-vaginal tissue and the common external and internal iliac nodal regions External beam radiation will be delivered in 180 cGy daily fractions to a total dose of 5040 cGy Patients will receive once a day treatment five days a week for approximately 6 weeks Concurrent chemotherapy andor intracavitary brachytherapy may be included in the treatment plan at the discretion of the treating physician consistent with routine clinical practice
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None